Tarlatamab
Tarlatamab is a bispecific T-cell engager (BiTE) antibody that bridges delta-like ligand 3 (DLL3)-expressing tumor cells with CD3-positive T cells, inducing T-cell-mediated cytotoxicity. It is approved for the treatment of extensive-stage small cell lung cancer after prior platinum-based chemotherapy, and is under investigation for bladder cancer and melanoma. DLL3 is highly expressed in small cell lung cancer and other neuroendocrine tumors, making it a highly selective therapeutic target.
Area Terapeutik
Mekanisme Kerja
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
Tarlatamab is a bispecific T-cell engager (BiTE) antibody that bridges delta-like ligand 3 (DLL3)-expressing tumor cells with CD3-positive T cells, inducing T-cell-mediated cytotoxicity. It is approved for the treatment of extensive-stage small cell lung cancer after prior platinum-based chemotherapy, and is under investigation for bladder cancer and melanoma. DLL3 is highly expressed in small cell lung cancer and other neuroendocrine tumors, making it a highly selective therapeutic target.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Tarlatamab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5095292. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tarlatamab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tarlatamab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tarlatamab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tarlatamab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tarlatamab"></drugfyi-drug>